| Zhang, Rui |
NCT06399185: Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort |
|
|
| Recruiting | 4 | 1740 | RoW | Normal saline, Placebo, Dexmedetomidine, Esketamine, Combined dexmedetomidine-esketamine | Peking University First Hospital, Peking University Shenzhen Hospital | Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine | 04/27 | 05/27 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
NCT05744063: A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients |
|
|
| Active, not recruiting | 4 | 13 | RoW | Emapalumab-Lzsg 5 MG/ML [Gamifant], Gamifant | Swedish Orphan Biovitrum | Primary Hemophagocytic Lymphohistiocytosis | 07/25 | 07/25 | | |
NCT03431428: Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients |
|
|
| Recruiting | 3 | 477 | RoW | transanal surgery, Miles surgery, Preoperative chemoradiotherapy | Zhang Rui | Almost-cCR, Surgery, Rectal Cancer | 01/20 | 12/22 | | |
NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases |
|
|
| Recruiting | 3 | 508 | RoW | mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab | Fudan University | Colorectal Cancer, Liver Metastases | 03/25 | 09/27 | | |
NCT05430698: PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma |
|
|
| Recruiting | 2 | 62 | RoW | PD-1antibody plus GEMOX | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Perihilar Cholangiocarcinoma | 01/24 | 10/25 | | |
NCT05997602: To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH |
|
|
| Recruiting | 2 | 56 | RoW | FCN-159 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Langerhans Cell Histiocytosis, LCH | 07/24 | 07/26 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05919095: A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer |
|
|
| Not yet recruiting | 2 | 37 | RoW | Carrilizumab plus GEMOX | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unresectable Gallbladder Cancer | 06/25 | 06/26 | | |
| Recruiting | N/A | 10254 | RoW | | Limeng Chen | Chronic Kidney Diseases, Chronic Kidney Disease-Mineral and Bone Disorder | 12/24 | 12/24 | | |
NCT05619861: CAR-T Cells in the Treatment of Malignant Hematological Tumors |
|
|
| Recruiting | N/A | 20 | RoW | CAR-T | Hebei Senlang Biotechnology Inc., Ltd., Cangzhou People's Hospital | Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell, Multiple Myeloma | 01/23 | 12/23 | | |
proOMCRC, NCT04716257: A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients |
|
|
| Recruiting | N/A | 400 | RoW | | West China Hospital, Sun Yat-sen University, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Changhai Hospital, Naval Medical University | Ovarian Metastasis, Colorectal Cancer | 09/25 | 09/25 | | |
| Recruiting | N/A | 280 | RoW | Virtual stent-guided incremental optimization strategy (VIOS), VIOS-based PCI, Standard angiographic strategy, angio-based PCI | China National Center for Cardiovascular Diseases | Percutaneous Coronary Intervention, Coronary Physiology, Computed Tomography | 06/25 | 12/25 | | |
| Recruiting | N/A | 1332 | RoW | The lying flat (0°-10°) head position for 72 hours, The The head elevation (30°-40°) position for 72 hours | Zhengzhou Yuan | Stroke, Acute, Endovascular Therapy | 11/25 | 04/26 | | |
NCT04737837: A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy |
|
|
| Not yet recruiting | N/A | 200 | RoW | lacosamide, Xinkang | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Epilepsy, Focal-Onset Seizure | 11/21 | 02/22 | | |
